AbCellera, a biotechnology firm that researches and develops human antibodies to address pandemics and common diseases, agreed to acquire OrthoMab. Financial terms were not disclosed. “Bispecifics have opened new vistas for antibody therapeutics and are the fastest growing format in clinical development. Despite this early success, the technological barriers for successful development of bispecifics, including challenges in discovery, pair selection, protein engineering and manufacturing, are keeping many firms out. By welcoming Tim to our team and OrthoMab into our stack, we have consolidated the talent and technologies needed to address these challenges. Through our partnerships, we’ll democratize access to leading bispecific technology across the industry, connecting science with technology to bring new therapies to the clinic,” Carl Hansen, Ph.D., AbCellera CEO.